Results 101 to 110 of about 35,949 (206)

Harnessing Aggregation‐Induced Emission for Advanced Disease Diagnosis: Mechanisms, Strategies and Future Perspectives

Medicine Bulletin, EarlyView.
The figure was created in BioRender.com. ABSTRACT Accurate and early diagnosis remains a key challenge in modern disease management. Conventional diagnostic methods often suffer from limitations in sensitivity, spatial resolution, and practical usability.
Zizhuo Du, Li Song, Xingrui Chen, Jun Jing, Yingchen Wang, Yue Jiang, Jiahui Gao, Dan Li, Feiran Xie, Peihong Xiao, Ben Zhong Tang   +10 more
wiley   +1 more source

Recent Advances in Exosome‐Based Nanodelivery Systems for Traumatic Brain Injury Treatment

Med Research, EarlyView.
An overview of functional modification, therapeutic effects, molecular composition, and delivery strategies for exosomes. ABSTRACT Traumatic brain injury (TBI) is a highly heterogeneous neurological condition with extremely high rates of mortality and disability.
Jue Zhu, Weiquan Liao, Ziqi Lian, Mengdan Zhang, Chenxing Wang, Xingjia Zhu, Lin Zhang, Jian Chen, Zhichao Lu, Peipei Gong   +9 more
wiley   +1 more source

Association Between Plasma Phosphorylated Tau‐217 and Cognition in Parkinson's Disease

Movement Disorders, EarlyView.
Abstract Background Alzheimer's disease (AD) co‐pathology contributes to dementia in PD, but its role in earlier cognitive impairment remains uncertain. Objective To determine if p‐tau217, a biomarker of early AD, is associated with cognitive impairment in PD.
Trycia Kouchache, Tevy Chan, Sophie Sun, Lang Liu, Aline Delva, Ziv Gan‐Or, Pedro Rosa‐Neto, Jean‐François Gagnon, Alain Dagher, Ronald B. Postuma, Madeleine Sharp   +10 more
wiley   +1 more source

Apathy in Lewy Body Disorders: A Position Paper

Movement Disorders, EarlyView.
Abstract Apathy is one of the most prevalent and disabling non‐motor symptoms in Parkinson's disease (PD) and dementia with Lewy bodies (DLB), collectively referred to as Lewy body disorders (LBDs). It is associated with reduced quality of life, accelerated cognitive decline, increased caregiver burden, and poorer functional outcomes, yet remains ...
Jaime Kulisevsky, Lidia Bojtos, Milica G. Kramberger, Elisa Mantovani, Iulia Murasan, Jose‐Alberto Palma, Karolina Poplawska‐Domaszewicz, Anna Sauerbier, Kallol Ray Chaudhuri, Per Odin, Daniel Weintraub, Anette Schrag, Cristian Falup‐Pecorariu   +12 more
wiley   +1 more source

Redefining CHI3L1: Therapeutic Opportunities at the Crossroads of Immune Suppression and Disease Progression

Medicinal Research Reviews, EarlyView.
ABSTRACT Chitinase‐3‐like‐1 (CHI3L1, also known as YKL‐40) has been recognized as a biomarker of inflammation and tissue remodeling and has now emerged as a pseudoenzymatic immune checkpoint. Recent structural, immunological, and translational studies redefine it as an active regulator of immune suppression rather than a passive disease marker. Despite
Kirti Upmanyu, Saurabh Upadhyay, Moustafa T. Gabr   +2 more
wiley   +1 more source

Amyloid-Related Imaging Abnormalities (ARIA) in Alzheimer's Disease. [PDF]

Dtsch Arztebl Int
Vöglein J, Levin J, Brendel M.
europepmc   +1 more source

Therapeutic Impact of GLP‐1 Receptor Agonists on Parkinson's Disease: A Scoping Review

Neurology and Clinical Neuroscience, EarlyView.
ABSTRACT No disease‐modifying treatment exists for Parkinson's disease (PD). Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) have gained attention as promising candidates for neuroprotection, given documented expression of GLP‐1 receptors within the central nervous system and the contribution of brain insulin resistance to dopaminergic ...
João Pedro Henriques, João Pedro Stringhetta Rahal, Rafael da Cunha Gomes Ribeiro, Enzo Bogucheski Ribeiro Machado, Carlos Antonio Negrato   +4 more
wiley   +1 more source

Volume change with gantenerumab: Impact of amyloid-related imaging abnormalities and amyloid removal. [PDF]

Alzheimers Dement
Tonietto M, Silvestri E, Belder CRS, Barkhof F, Fox NC, Smith J, Klein G.   +6 more
europepmc   +1 more source

Serum elemental profile‐based machine learning models for Alzheimer's disease identification and cognitive score prediction

Neuroprotection, EarlyView.
Serum elemental profiling combined with machine learning supports exploratory Alzheimer's disease (AD) identification and cognitive score prediction. In this retrospective cross‐sectional study, 874 participants from the BANC‐PUMC, including cognitively normal controls and patients with AD, were analyzed.
Haotian Liu, Xinnan Liu, Yashuang Chen, Meng Pan, Ying Fu, Chao Ma, Wei Ge   +6 more
wiley   +1 more source

Reduced diffusion associated with amyloid-related imaging abnormalities in three patients treated with donanemab. [PDF]

Neurocase
Schwartz NU, Dietz CD, Lin Z, Tammewar G, Bui N, La Joie R, Wang Y, Sreekrishnan A, Suhami D, VandeVrede L, Ljubenkov PA, Rojas JC.   +11 more
europepmc   +1 more source